Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials

被引：0
|
作者：
Lebbe, Celeste
Weber, Jeffrey S.
Maio, Michele
Neyns, Bart
Harmankaya, Kaan
Hamid, Omid
O'Day, Steven
Chin, Kevin M.
McDowell, Diane Opatt
Cykowski, Lori
McHenry, Brent
Wolchok, Jedd D.
机构：
[1] Hop St Louis, Paris, France
[2] Comprehens Melanoma Res Ctr, Moffitt Canc Ctr, Tampa, FL USA
[3] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy
[4] UZ Brussel, Brussels, Belgium
[5] Med Univ Vienna, Div Gen Dermatol, Dept Dermatol, Vienna, Austria
[6] Angeles Clin & Res Inst, Santa Monica, CA USA
[7] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9053
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-term survival in metastatic uveal melanoma (MUM)
    Neumann, Sophie Piperno
    Dureau, Sylvain
    Rodrigues, Manuel Jorge
    Desjardins, Laurence
    Pierron, Gaelle
    Levy-Gabriel, Christine
    Lumbroso, Livia
    Servois, Vincent
    Najean, Marie
    Savignoni, Alexia
    Cassoux, Nathalie
    Mariani, Pascale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
    Long, Georgina, V
    Eroglu, Zeynep
    Infante, Jeffrey
    Patel, Sapna
    Daud, Adil
    Johnson, Douglas B.
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Sharfman, William
    McWilliams, Robert
    Sznol, Mario
    Redhu, Suman
    Gasal, Eduard
    Mookerjee, Bijoyesh
    Weber, Jeffrey
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 667 - +
  • [33] IPILIMUMAB IMPROVES OVERALL SURVIVAL IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: LONG-TERM SURVIVAL RESULTS FROM A PHASE III TRIAL
    Haanen, J. B.
    Hodi, F. S.
    O'Day, S. J.
    McDermott, D. F.
    Robert, C.
    Schadendorf, D.
    van den Eertwegh, A. J.
    Chen, T.
    Hoos, A.
    Urba, W. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 402 - 402
  • [34] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
  • [35] Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma
    Bedikian, Agop Y.
    Johnson, Marcella M.
    Warneke, Carla L.
    Papadopoulos, Nicholas E.
    Kim, Kevin
    Hwu, Wen-Jen
    Mclntyre, Susan
    Hwu, Patrick
    CANCER INVESTIGATION, 2008, 26 (06) : 624 - 633
  • [36] Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting
    B. M. Lang
    A. Peveling-Oberhag
    D. Faidt
    A. M. Hötker
    V. Weyer-Elberich
    S. Grabbe
    C. Loquai
    Medical Oncology, 2018, 35
  • [37] Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials
    Neyns, Bart
    Weber, Jeffrey S.
    Lebbe, Celeste
    Maio, Michele
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Sato, T.
    Ikeguchi, A. P.
    Nathan, P.
    Carvajal, R. D.
    Shoushtari, A. N.
    Gajewski, T. F.
    Hassel, J. C.
    Rioth, M.
    Leyvraz, S.
    Daniels, G. A.
    Hernandez-Aya, L.
    Johnson, D. B.
    Kim, K.
    Piulats Rodriguez, J. M.
    Cowey, C. L.
    Lockwood, S.
    Collins, L.
    Karakuzu, O.
    Sacco, J. J.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S934 - S935
  • [39] Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
    Weber, Jeffrey
    Gibney, Geoffrey
    Kudchadkar, Ragini
    Yu, Bin
    Cheng, Pingyan
    Martinez, Alberto J.
    Kroeger, Jodie
    Richards, Allison
    McCormick, Lori
    Moberg, Valerie
    Cronin, Heather
    Zhao, Xiuhua
    Schell, Michael
    Chen, Yian Ann
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (04) : 345 - 353
  • [40] PROJECTING LONG TERM OVERALL SURVIVAL BENEFIT IN METASTATIC MELANOMA PATIENTS TREATED WITH IPILIMUMAB USING EXTRAPOLATION METHODS
    Kim, Hansoo
    Cook, Greg
    McCloud, Philip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 313 - 313
12345